A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...
A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results